In some other jurisdictions, tirzepatide may be available for weight management under the brand name Zepbound
J Diabetes Sci Technol Eberle C, Stichling S (2021) Effect of telemetric interventions on glycated hemoglobin A1c and management of type 2 diabetes mellitus: systematic meta-review
The pooled GLP1-RA analysis demonstrated benefits in the secondary endpoints as well, with a 13% reduction in cardiovascular death [HR, 0.87 (0.800.94)], 10% reduction in MI [HR, 0.90 (0.830.98)], 17% reduction in stroke [HR, 0.83 (0.760.92)], 11% reduction in heart failure hospitalizations [HR, 0.89 (0.820.98)], and 12% reduction in all-cause mortality [HR, 0.88 (0.820.94)] [26]
Now I understand what it means when someone tells you, Its the system thats not allowing us. So thank you for that
Sources FDA Wegovy Cardiovascular Risk-Reduction Approval FDA Wegovy Prescribing Information New England Journal of Medicine SELECT Trial: Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes American College of Cardiology SELECT Clinical Trial Summary American Heart Association Lifes Essential 8 CDC Heart Disease Risk Factors CDC Risk Factors for High Cholesterol NIDDK Health Risks of Overweight and Obesity Dr
Overall, 8% of the sample reported having used a GLP-1 drug.
